학술논문
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial
Document Type
Short Communication
Author
Garon, Edward B.; Spira, Alexander I.; Goldberg, Sarah B.; Chaft, Jamie E.; Papadimitrakopoulou, Vassiliki; Cascone, Tina; Antonia, Scott J.; Brahmer, Julie R.; Camidge, D. Ross; Powderly, John D.; Wozniak, Antoinette J.; Felip, Enriqueta; Wu, Song; Ascierto, Maria L.; Elgeioushi, Nairouz; Awad, Mark M.
Source
In Journal of Thoracic Oncology August 2023 18(8):1094-1102
Subject
Language
ISSN
1556-0864